Literature DB >> 19844223

How will GINA influence participation in pharmacogenomics research and clinical testing?

L G Dressler1, S F Terry.   

Abstract

After a 13-year battle in Congress--longer than it took to map the human genome--the Genetic Information Nondiscrimination Act (GINA) was passed into law on 21 May 2008. Before its passing, Francis Collins, then director of the National Human Genome Research Institute, testified before the 110th Congress that the success of personalized medicine hinged on the passing of the legislation. How will GINA, which takes effect in 2009, influence participation in pharmacogenomic research and clinical testing?

Entities:  

Mesh:

Year:  2009        PMID: 19844223     DOI: 10.1038/clpt.2009.146

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  13 in total

1.  Consumer awareness and attitudes about insurance discrimination post enactment of the Genetic Information Nondiscrimination Act.

Authors:  Dawn C Allain; Sue Friedman; Leigha Senter
Journal:  Fam Cancer       Date:  2012-12       Impact factor: 2.375

Review 2.  Breaking barriers in the genomics and pharmacogenetics of drug addiction.

Authors:  M K Ho; D Goldman; A Heinz; J Kaprio; M J Kreek; M D Li; M R Munafò; R F Tyndale
Journal:  Clin Pharmacol Ther       Date:  2010-10-27       Impact factor: 6.875

3.  Pharmacogenetics, cost of genotyping, and guidelines for individualizing therapy with mercaptopurine in pediatric acute lymphoblastic leukemia.

Authors:  Gabriele Stocco; Kristine R Crews
Journal:  Pediatr Blood Cancer       Date:  2011-07-27       Impact factor: 3.167

Review 4.  Ethical considerations for pharmacogenomic testing in pediatric clinical care and research.

Authors:  Cassandra Moran; Courtney D Thornburg; Raymond C Barfield
Journal:  Pharmacogenomics       Date:  2011-06       Impact factor: 2.533

5.  Clinical implementation of pharmacogenomics: overcoming genetic exceptionalism.

Authors:  Mary V Relling; Russ B Altman; Matthew P Goetz; William E Evans
Journal:  Lancet Oncol       Date:  2010-04-21       Impact factor: 41.316

6.  Return of research results from pharmacogenomic versus disease susceptibility studies: what's drugs got to do with it?

Authors:  Lynn G Dressler
Journal:  Pharmacogenomics       Date:  2012-06       Impact factor: 2.533

7.  Thematic analysis of cardiac care patients' explanations for declining contribution to a genomic research-based biobank.

Authors:  Pamela Holtzclaw Williams; Lynne S Nemeth; Jennifer E Sanner; Lorraine Q Frazier
Journal:  Am J Crit Care       Date:  2013-07       Impact factor: 2.228

Review 8.  Pharmacogenomics and adverse drug reactions in children.

Authors:  Michael J Rieder; Bruce Carleton
Journal:  Front Genet       Date:  2014-04-16       Impact factor: 4.599

9.  Disease advocacy organizations catalyze translational research.

Authors:  Sharon F Terry
Journal:  Front Genet       Date:  2013-06-04       Impact factor: 4.599

10.  Scientific challenges and implementation barriers to translation of pharmacogenomics in clinical practice.

Authors:  Y W Francis Lam
Journal:  ISRN Pharmacol       Date:  2013-02-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.